Sponsored by 
Monday June 10, 2024 | 15.30-18.00
As high interest rates and inflation continue to put pressure on the margins of ophthalmology groups, the playbook, particularly for private equity-backed groups has changed. Buy and build opportunities will only go so far and instead, groups must focus on other value-generating activities, process standardisation and optimisation to grow their top line and bottom line.
The demographic tailwinds remain strong and the dawn of new therapeutics to treat Dry AMD means that there continue to be huge opportunities in the space. But challenges remain around full-reimbursement, new payment models and standardising care delivery i.e. capitalizing on digitalization opportunities for the respective disease workflows.
Groups need to decide what services to offer mixed with the right commercial model. Do they have to offer a complete spectrum of services to be successful or can they pick and choose the activities with the best margin? How do they ensure that their models are sustainable and can deliver care for the medium to long term?
An image and data-rich discipline, the sector has the perfect conditions for AI and other technologies to make a huge and meaningful impact on patient access and outcomes. What investments should be made in tech and what has the potential to make the biggest impact?
Why Attend:
This CxO roundtable discussion is an opportunity for providers and investors to come together in a non-competitive environment and discuss what the new ophthalmology playbook should be. It is a chance to bounce ideas off of one another and explore what investments in technology and infrastructure are needed to ensure the sector’s longevity and sustainability.
The roundtable features insights, lessons learned and follow-up discussion with contributions from Franz-Robert Klingan, Partner, Bain & Company, Darshak Shah, Founder and Non Executive Director, NewMedica, Johanna Oberg, CEO Commercial Care, Bergman Clinics and Georgy Shakirin, Head of AI, Carl Zeiss Meditec AG.
Space is limited so this CXO session is strictly by invitation only.
You can apply for an invitation via this form.